Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.

<h4>Background</h4>In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masashi Ishikawa, Atsuo Takashima, Yusuke Nagata, Ryoichi Sawada, Masahiko Aoki, Hiroshi Imazeki, Hidekazu Hirano, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Ken Kato, Masayuki Saruta, Narikazu Boku
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/80f72f9eb44243b8941b7eac292aa720
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:80f72f9eb44243b8941b7eac292aa720
record_format	dspace
spelling	oai:doaj.org-article:80f72f9eb44243b8941b7eac292aa7202021-12-02T20:08:00ZTumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.1932-620310.1371/journal.pone.0257551https://doaj.org/article/80f72f9eb44243b8941b7eac292aa7202021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257551https://doaj.org/toc/1932-6203<h4>Background</h4>In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR).<h4>Methods</h4>The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx.<h4>Results</h4>Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR <0, which indicates tumor shrinkage, was obtained in 13 of 30 cases (43.3%). The median progression-free survival and overall survival after Re-Cx were 3.8 and 6.57 months, respectively.<h4>Conclusion</h4>We found that Re-Cx may have some anti-tumor efficacy as salvage treatment for mCRC and these results also suggested the clinical benefits of Re-Cx.Masashi IshikawaAtsuo TakashimaYusuke NagataRyoichi SawadaMasahiko AokiHiroshi ImazekiHidekazu HiranoHirokazu ShojiYoshitaka HonmaSatoru IwasaNatsuko OkitaKen KatoMasayuki SarutaNarikazu BokuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257551 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Masashi Ishikawa Atsuo Takashima Yusuke Nagata Ryoichi Sawada Masahiko Aoki Hiroshi Imazeki Hidekazu Hirano Hirokazu Shoji Yoshitaka Honma Satoru Iwasa Natsuko Okita Ken Kato Masayuki Saruta Narikazu Boku Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
description	<h4>Background</h4>In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR).<h4>Methods</h4>The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx.<h4>Results</h4>Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR <0, which indicates tumor shrinkage, was obtained in 13 of 30 cases (43.3%). The median progression-free survival and overall survival after Re-Cx were 3.8 and 6.57 months, respectively.<h4>Conclusion</h4>We found that Re-Cx may have some anti-tumor efficacy as salvage treatment for mCRC and these results also suggested the clinical benefits of Re-Cx.
format	article
author	Masashi Ishikawa Atsuo Takashima Yusuke Nagata Ryoichi Sawada Masahiko Aoki Hiroshi Imazeki Hidekazu Hirano Hirokazu Shoji Yoshitaka Honma Satoru Iwasa Natsuko Okita Ken Kato Masayuki Saruta Narikazu Boku
author_facet	Masashi Ishikawa Atsuo Takashima Yusuke Nagata Ryoichi Sawada Masahiko Aoki Hiroshi Imazeki Hidekazu Hirano Hirokazu Shoji Yoshitaka Honma Satoru Iwasa Natsuko Okita Ken Kato Masayuki Saruta Narikazu Boku
author_sort	Masashi Ishikawa
title	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
title_short	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
title_full	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
title_fullStr	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
title_full_unstemmed	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
title_sort	tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: a retrospective study.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/80f72f9eb44243b8941b7eac292aa720
work_keys_str_mv	AT masashiishikawa tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT atsuotakashima tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT yusukenagata tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT ryoichisawada tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT masahikoaoki tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT hiroshiimazeki tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT hidekazuhirano tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT hirokazushoji tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT yoshitakahonma tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT satoruiwasa tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT natsukookita tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT kenkato tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT masayukisaruta tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy AT narikazuboku tumorgrowthrateduringrechallengechemotherapywithpreviouslyusedagentsassalvagetreatmentformetastaticcolorectalcanceraretrospectivestudy
_version_	1718375252558348288

Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.

Ejemplares similares